- Home
- COYA vs AGEN Comparison
COYA vs AGEN Comparison
Compare COYA & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | AGEN |
|---|---|---|
| Founded | 2020 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 126.2M |
| IPO Year | 2022 | 1999 |
Fundamental Metrics
Financial Performance| Metric | COYA | AGEN |
|---|---|---|
| Price | $4.65 | $3.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $15.80 | $14.50 |
| AVG Volume (30 Days) | 148.1K | ★ 484.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | $3,554,061.00 | ★ $42,877,086.00 |
| Revenue This Year | $70.00 | $5.19 |
| Revenue Next Year | N/A | $68.25 |
| P/E Ratio | ★ N/A | $8.27 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $3.94 | $1.38 |
| 52 Week High | $8.29 | $7.34 |
Technical Indicators
Market Signals| Indicator | COYA | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 47.18 |
| Support Level | $4.41 | $2.90 |
| Resistance Level | $6.15 | $3.15 |
| Average True Range (ATR) | 0.28 | 0.18 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 29.67 | 67.29 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).